Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria

Soumya Palliyil, Ian D Broadbent

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The rise in infections caused by Gram-negative bacteria and the spread of resistance to conventional antibiotics provide significant challenges to the pharmaceutical industry. Monoclonal antibodies have achieved impressive recent clinical successes in a variety of indications, but to date there are no licensed immunotherapeutics that target bacterial infections, despite several promising studies in animal models of infection. Several key questions remain, in particular relating to the target(s), mechanism of action, and mode of delivery of any potential novel immunotherapeutic. This short review discusses recent approaches being taken to develop novel immunotherapeutic molecules for the treatment of Gram-negative bacterial infections.

Original languageEnglish
Pages (from-to)566-570
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume9
Issue number5
DOIs
Publication statusPublished - Oct 2009

Keywords

  • animals
  • anti-bacterial agents
  • antibodies, monoclonal
  • antigens, bacterial
  • bacterial vaccines
  • drug design
  • drug resistance, bacterial
  • gram-negative bacteria
  • gram-negative bacterial infections
  • humans
  • immunotherapy
  • treatment outcome

Fingerprint Dive into the research topics of 'Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria'. Together they form a unique fingerprint.

  • Cite this